Invivyd (IVVD) shares fell past 12% in recent Tuesday trading after the biopharmaceutical company withdrew prior revenue guidance.
The company said the move was "due to recent growth headwind from US FDA's late-Q3 2024 warning on potential for substantially reduced activity of pemivibart through the Pemgarda Fact Sheet and other media based on contested, third-party, non-peer-reviewed, non-reproducible, virologic activity data from a non-pemivibart antibody."
The company previously guided to $150 million to $200 million in Pemgarda net product revenue in 2024 and expected to finish the year with $75 million or more in cash and cash equivalents.
Invivyd said its preliminary net product revenue now stands at $9.3 million for Q3 from Pemgarda, and it estimates it ended the quarter with about $107 million in cash and equivalents.
Price: 0.93, Change: -0.12, Percent Change: -11.06
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。